vascuCAP vs cvi42 Auto Imaging

For a physician evaluating AI tools for cardiovascular imaging, vascuCAP (now ElucidVivo/PlaqueIQ) and cvi42 Auto Imaging offer distinct strengths. vascuCAP excels in detailed plaque characterization from CT angiography, providing histologically-validated quantification of plaque components like lipid-rich necrotic core and calcification. This makes it particularly strong for cardiovascular risk stratification and optimizing treatment decisions based on plaque vulnerability. Its deployment options include both cloud and on-premise, and it boasts explicit HIPAA compliance and FDA clearance.

In contrast, cvi42 Auto Imaging offers a broader, multi-modality approach, analyzing both cardiac MR and CT images for comprehensive cardiovascular assessment. While it also includes plaque assessment, its key practical difference lies in its extensive capabilities for cardiac MR analysis, including function, flow, tissue characterization, and strain. This makes it ideal for practices requiring a versatile tool for various cardiovascular imaging needs beyond just plaque. Physicians primarily focused on in-depth plaque composition analysis and risk stratification from CTAs might lean towards vascuCAP, while those needing a more comprehensive, multi-modality solution for both MR and CT, including advanced cardiac function analysis, would likely find cvi42 Auto Imaging more suitable.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist